Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Cholestin marketer secures exclusive multi-level marketing channel rights to Policor policosanol under agreement with Hauser, firms announce Oct. 3. Hauser becomes sole supplier of beeswax-derived ingredient for use in Pharmanex' Cholestin, Cardio Formula supplements. Two days earlier, Hauser announced it exercised an option to purchase policosanol technology, intellectual property rights from an unidentified "developmental start-up company" for undisclosed terms. Hauser has manuyfactured Policor since February; Pharmanex debuted reformulated Cholestin in July after losing a lengthy court battle with FDA over use of red yeast rice in the product (1"The Tan Sheet" July 16, In Brief)

You may also be interested in...


New formulation contains Policor (policosanol), "beeswax-based" proprietary ingredient that inhibits cholesterol synthesis in liver, Pharmanex says July 9. NuSkin Enterprises division removed original red yeast rice-containing Cholestin from market following Utah federal court decision favoring FDA determination the product was a drug because it contained lovastatin, the active ingredient in Merck's Mevacor (1"The Tan Sheet" May 7, p. 15). Once-daily formula developed by Hauser replaces twice-daily red yeast rice dosage and is made with novel PoliSorb softgel delivery system. Thirty-count bottles marked "new and improved" are priced at $39.95

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts